

PERSONAL INFORMATION

Constantinos Markopoulos

WORK EXPERIENCE

July 2016–Present

Clinical Assessor in Human Medicines Evaluation Section

National Organization for Medicines (Greece)

Clinical Assessment of applications for approvals and variations of Analgesic, Anti-inflammatory, Topical medicines.

November 2018–Present

CHMP Member

European Medicines Agency (Netherlands)

EDUCATION AND TRAINING

October 1999–September 2004

Bachelor

National and Kapodistrian University of Athens, Faculty of Pharmacy (Greece)

Pharmaceutical Sciences

October 2004–May 2007

Master

National and Kapodistrian University of Athens, Faculty of Pharmacy (Greece)

Subject: Industrial Pharmacy

Thesis: "Contribution to understanding of oleuropein absorption after per os administration"

July 2007–April 2012

PhD

National and Kapodistrian University of Athens, Faculty of Pharmacy (Greece)

Subject: Biopharmaceutics

Thesis: "In vitro drug permeability studies from intestinal contents and simulated intestinal contents"

January 2013–July 2014

Postdoctoral Research Fellow

National and Kapodistrian University of Athens, Faculty of Pharmacy (Greece)

Innovative Medicines Initiative project "OrBiTo"

Subject: "Development of methods using biorelevant media and USP 2 / USP 4 apparatus for assessing the dissolution of modified release dosage forms in the lower intestine/gastrointestinal tract, respectively"

January 2011–November 2017

Bachelor

National and Kapodistrian University of Athens, Department of History and Philosophy of Science (Greece)

Subject: History and Philosophy of Science

Thesis: "Serendipity in Drug Discovery"

ADDITIONAL INFORMATION

Expertise

Biopharmaceutics, drug absorption, drug permeation, drug dissolution, biorelevant media, biowaivers

Publications

1. Andreas CJ, Pepin X, Markopoulos C, Vertzoni M, Reppas C, Dressman JB. Mechanistic investigation of the negative food effect of modified release zolpidem. Eur J Pharm Sci. 102:284-298 (2017)

2. Andreas C, Chen YC, Markopoulos C, Reppas C, Dressman J. In-vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. *Eur J Pharm Biopharm.* 97(Pt A):39-50 (2015)
3. Reppas C, Karatza E, Goumas C, Markopoulos C, Vertzoni M. Characterization of contents of distal ileum and cecum to which drugs/drug products are exposed during bioavailability/bioequivalence studies in healthy adults. *Pharm Res.* 32(10):3338-49 (2015)
4. Markopoulos C, Vertzoni M, Symillides M, Kesisoglou F, Reppas C. Two-stage single-compartment models to evaluate dissolution in the lower intestine. *J Pharm Sci.* 104 (9): 2986-97 (2015)
5. Markopoulos C, Andreas CJ, Vertzoni M, Dressman J, Reppas C. In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media. *Eur J Pharm Biopharm.* 93: 173–182 (2015)
6. Markopoulos C, Thoenen F, Preisig D, Symillides M, Vertzoni M, Parrott N, Reppas C, Imanidis G. Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness. *Eur J Pharm Biopharm.* 86 (3): 438-48 (2014)
7. Markopoulos C, Imanidis G, Vertzoni M, Symillides M, Parrott N, Reppas C. In vitro and ex vivo investigation of the impact of luminal lipid phases on passive permeability of lipophilic small molecules using PAMPA. *Pharm Res.* 30 (12): 3145-53 (2013)
8. Vertzoni M, Markopoulos C, Symillides M, Goumas C, Imanidis G, Reppas C. Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across Caco-2 cell monolayers. *Mol Pharm.* 9:1189-98 (2012)
9. Markopoulos C, Vertzoni M, Agalias A, Magiatis P, Reppas C. Stability of oleuropein in the human proximal gut. *J Pharm Pharmacol.* 61:143-9 (2009)

Projects Innovative Medicines Initiative project “OrBiTo”

Memberships

Other Relevant Information Foreign languages: English, German, Spanish